Cigna Corp. (CI - Free Report) came up with adjusted earnings of $4.54 per share in third-quarter 2019, surpassing the Zacks Consensus Estimate by 3.84%. Quarterly earnings were up 18% year over year.
Cigna’s revenues of $35.8 billion beat the Zacks Consensus Estimate by 5%. Revenues grew 214% year over year owing to the acquisition of Express Scripts.
Among the revenue components, pharmacy revenues were $25.9 billion compared with $747 million in the year-ago quarter, premiums were up 10.5% year over year to $9.9 billion while fees increased 68% to $2.3 billion. The growth in pharmacy revenues was backed by the acquisition of pharmacy benefit manager Express Scripts.
Cigna Corporation Price, Consensus and EPS Surprise
The SG&A expense ratio was 9.2% for third-quarter 2019, down from 23.8% in the year-ago quarter. The decline was mainly led by business mix changes resulting from the Express Scripts combination and the health insurance tax suspension.
The company’s medical enrollment grew by 212,000 lives from the prior-year quarter to 17.07 million customers, driven by growth in Government, Commercial and International markets. Moreover, the acquisition of Express Scripts, completed last December, led to an increase in Pharmacy and Medicare Part D members.
Cigna’s debt-to-capitalization ratio improved to 46.4% as on Sep 30, 2019, from 50.9% as of Dec 31, 2018.
For 2019, the company expects earnings per share in the range of $16.8-$17 compared with the previous guidance of $16.6-$16.9.
Total revenues are expected to be $138 billion (versus $136-$137 billion expected earlier) and medical customers are projected to grow by approximately 200,000.
Medical care ratio is expected in the range of 80.8-81.2% versus previous estimate of 80.5-81.5%.
For 2020, the company projects Health Services’ retention rate of 97% for the 2019 selling season for pharmacy services. Health Services’ adjusted pharmacy scripts are expected to grow between 25 million and 35 million organically in 2020.
Cigna is well poised for the long term due to its recent acquisition of pharmacy benefit manager, Express Scripts, which provides a nice diversification to its existing businesses, namely administrative services, international operations, and disability and life insurance.
The combination of Express Scripts’ pharmacy benefit business and Cigna’s health insurance business will help control drug pricing cost to a large extent, which is one of the biggest components of soaring medical costs. The company has better control over its medical cost compared with other players in the industry. The decline in medical costs should further aid its margins.
Another distinguishing feature of the company is the international business, which provides additional diversification opportunities. Its strong balance sheet is another positive.
Zacks Rank and Other Releases
Cigna currently carries a Zacks Rank #3 (Hold).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Other players in the medical space that have reported third-quarter earnings so far are UnitedHealth Group, Inc. (UNH - Free Report) , Anthem Inc. (ANTM - Free Report) and Wellcare Health Plans, Inc. , each beating the Zacks Consensus Estimate by 3.47%, 0.62% and 39.95%, respectively.
Free: Zacks’ Single Best Stock Set to Double
Today you are invited to download our just-released Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.
Download Free Report Now >>